MDXG · Mimedx Group, Inc.
10 customers — 22% of revenue (the year ended December 31, 2025)
“For the years ended December 31, 2025, 2024, and 2023, our top ten customers accounted for 22%, 20% and 20%, respectively, of our net sales”
Key customers — 1% of revenue (the year ended December 31, 2025)
“net sales to all U.S. government accounts comprised approximately 1%, 1% and 2%, respectively, of our net sales.”
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -19.69M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | -16% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EPS non-GAAP | -$0.05 | three months ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | $89.9M | six months ended June 30, 2026 | — |
| Adjusted Gross Profit Margin non-GAAP | 72.8% | six months ended June 30, 2026 | — |
| Adjusted net (loss) income non-GAAP | -14.08M | Six Months Ended June 30, 2026 | — |
| Free Cash Flow non-GAAP | -$9.3M | Six Months Ended June 30, 2026 | — |
| Gross Profit Margin, as adjusted non-GAAP | 72.8% | Six Months Ended June 30, 2026 | — |
| Surgical Growth | 15% | Q2 2026 vs Q2 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDXG
this stock
Mimedx Group, Inc.
|
$648.63M | -36.5% | +20.0% | 111.3 | 5.8% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDXG | +2.4% | +4.1% | -12.1% | +4.1% | -36.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.3% | +0.8% | -23.2% | +2.0% | -48.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.